SELLAS Life Sciences Group (SLS) is down 8.6% today. Here is some analysis on what might have caused this price movement.
Analysis: The catalyst is not fully clear, and the move looks more like a pullback after a sharp late-June run tied to anticipation around the company’s pivotal AML data. This could be because traders are taking profits while waiting for the Phase 3 REGAL trial to hit its final event threshold and produce topline results, with no fresh company press release posted since mid-May.
Details:
SELLAS said on May 12 that its Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia had reached 78 of the 80 required events that trigger final analysis.The company also said it would announce an update once the 80th event is reached, leaving the stock highly sensitive to timing expectations around that binary readout.SELLAS reported $107.1 million of cash and cash equivalents as of March 31, 2026, then disclosed on June 2 that it received about $28.7 million from warrant exercises in April and May.A June 24 filing updated executive severance and change-of-control arrangements, which appears to have added takeover speculation to the story and may have contributed to the stock’s prior surge, making a reversal easier once momentum cooled.Sources:
SELLAS Life Sciences Investor Relations, SEC, Simply Wall St
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
Quiver Alerts
Receive SLS Data Alerts
Get market-moving data, filings, and signals for SLS in real time.
Sign Up
$SLS Hedge Fund Activity
We have seen 108 institutional investors add shares of $SLS stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 6,208,185 shares (+283.7%) to their portfolio in Q1 2026, for an estimated $26,260,622
- BLACKROCK, INC. added 4,657,356 shares (+61.8%) to their portfolio in Q1 2026, for an estimated $19,700,615
- JONES FINANCIAL COMPANIES LLLP added 1,245,834 shares (+290.2%) to their portfolio in Q1 2026, for an estimated $5,269,877
- MILLENNIUM MANAGEMENT LLC removed 1,228,325 shares (-88.5%) from their portfolio in Q1 2026, for an estimated $5,195,814
- GEODE CAPITAL MANAGEMENT, LLC added 835,269 shares (+27.1%) to their portfolio in Q1 2026, for an estimated $3,533,187
- UBS GROUP AG added 696,692 shares (+1429.8%) to their portfolio in Q1 2026, for an estimated $2,947,007
- MARSHALL WACE, LLP added 696,494 shares (+52.0%) to their portfolio in Q1 2026, for an estimated $2,946,169
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Why SELLAS Life Sciences Group (SLS) Stock Is Down Today
SELLAS Life Sciences Group (SLS) is down 8.6% today. Here is some analysis on what might have caused this price movement.
Analysis: The catalyst is not fully clear, and the move looks more like a pullback after a sharp late-June run tied to anticipation around the company’s pivotal AML data. This could be because traders are taking profits while waiting for the Phase 3 REGAL trial to hit its final event threshold and produce topline results, with no fresh company press release posted since mid-May.
Details:
Sources:
SELLAS Life Sciences Investor Relations, SEC, Simply Wall St
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$SLS Hedge Fund Activity
We have seen 108 institutional investors add shares of $SLS stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »